Adrenal adrenaline- and noradrenaline-containing cells and celiac sympathetic ganglia are differentially controlled by centrally administered corticotropin-releasing factor and arginine-vasopressin in rats.
The adrenal glands and sympathetic celiac ganglia are innervated mainly by the greater splanchnic nerves, which contain preganglionic sympathetic nerves that originated from the thoracic spinal cord. The adrenal medulla has two separate populations of chromaffin cells, adrenaline-containing cells (A-cells) and noradrenaline-containing cells (NA-cells), which have been shown to be differentially innervated by separate groups of the preganglionic sympathetic neurons. The present study was designed to characterize the centrally activating mechanisms of the adrenal A-cells, NA-cells and celiac sympathetic ganglia with expression of cFos (a marker for neural excitation), in regard to the brain prostanoids, in anesthetized rats. Intracerebroventricularly (i.c.v.) administered corticotropin-releasing factor (CRF) induced cFos expression in the adrenal A-cells, but not NA-cells, and celiac ganglia. On the other hand, i.c.v. administered arginine-vasopressin (AVP) resulted in cFos induction in both A-cells and NA-cells in the adrenal medulla, but not in the celiac ganglia. Intracerebroventricular pretreatment with indomethacin (an inhibitor of cyclooxygenase) abolished the CRF- and AVP-induced cFos expression in all regions described above. On the other hand, intracerebroventricular pretreatment with furegrelate (an inhibitor of thromboxane A2 synthase) abolished the CRF-induced cFos expression in the adrenal A-cells, but not in the celiac ganglia, and also abolished the AVP-induced cFos expression in both A-cells and NA-cells in the adrenal medulla. These results suggest that centrally administered CRF activates adrenal A-cells and celiac sympathetic ganglia by brain thromboxane A2-mediated and other prostanoid than thromboxane A2 (probably prostaglandin E2)-mediated mechanisms, respectively. On the other hand, centrally administered AVP activates adrenal A-cells and NA-cells by brain thromboxane A2-mediated mechanisms in rats.
Yamaguchi-Shima
Naoko
N
Department of Pharmacology, Graduate School of Medicine, Kochi University, Nankoku, Kochi 783-8505, Japan. ynaoko@kochi-u.ac.jp
Okada
Shoshiro
S
Shimizu
Takahiro
T
Usui
Daisuke
D
Nakamura
Kumiko
K
Lu
Lianyi
L
Yokotani
Kunihiko
K
D000313:Adrenal Medulla / Q000187:drug effects / Q000294:innervation / Q000378:metabolism*; D000818:Animals; D016718:Arachidonic Acid / Q000378:metabolism / Q000502:physiology; D001127:Arginine Vasopressin / Q000494:pharmacology*; D001572:Benzofurans / Q000494:pharmacology; D001921:Brain / Q000166:cytology / Q000378:metabolism; D003346:Corticotropin-Releasing Hormone / Q000494:pharmacology*; D004837:Epinephrine / Q000378:metabolism; D005728:Ganglia, Sympathetic / Q000187:drug effects / Q000378:metabolism*; D015870:Gene Expression; D016762:Genes, fos / Q000187:drug effects; D007213:Indomethacin / Q000494:pharmacology; D007276:Injections, Intraventricular; D008297:Male; D009638:Norepinephrine / Q000378:metabolism; D010784:Photomicrography; D011453:Prostaglandins / Q000378:metabolism / Q000502:physiology; D051381:Rats; D017208:Rats, Wistar; D013928:Thromboxane A2 / Q000378:metabolism* / Q000502:physiology
D001572:Benzofurans; D011453:Prostaglandins; D001127:Arginine Vasopressin; D016718:Arachidonic Acid; D013928:Thromboxane A2; D003346:Corticotropin-Releasing Hormone; C039936:furegrelate; D009638:Norepinephrine; D007213:Indomethacin; D004837:Epinephrine